Adaptimmune Appoints Lawrence M. Alleva to its Board of Directors
News Mar 11, 2015
Adaptimmune has announced the appointment of Lawrence (Larry) M. Alleva, to its Board of Directors as an independent, non-executive director with immediate effect. Mr. Alleva will also serve as chairman of the Board Audit Committee.
Mr. Alleva is a former partner with PricewaterhouseCoopers LLP (PwC), where he worked for 39 years until his retirement in June 2010, including 28 years’ service as a partner. Mr. Alleva worked with numerous pharmaceutical and biotechnology companies as clients and, additionally, served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm’s Assurance Practice from 2006 until his retirement.
Mr. Alleva currently serves as a director for public companies Tesaro Inc. and Bright Horizons Family Solutions Inc., and for privately held Mirna Therapeutics Inc., and chairs the audit committee for those companies. He previously served on the board of GlobalLogic, Inc. through the sale of the company in 2013 and also chaired the audit committee. Mr. Alleva is a Certified Public Accountant (inactive). He received a Bachelor of Science degree in Accounting from Ithaca College and attended Columbia University’s Executive MBA non-degree program.
“I am delighted that such a high caliber individual as Larry Alleva has agreed to join our Board of Directors,” said Dr. Jonathan Knowles, Chairman of Adaptimmune. “His substantial corporate finance and accounting expertise, combined with his extensive experience of supporting growing biotech firms, brings significant added value to the Company, and complements the skills and experience of our other Board members.”
Mr. Alleva said: “I am very pleased to be joining Adaptimmune at this interesting time, and I look forward to working closely with the team as we aim to build the Company up with the expansion of its UK and US operations.”
Almost 95% of people with early-diagnosed breast cancer will require surgery and it’s often the first line of treatment for people with brain tumors, for example. But despite improvements in surgical techniques over the past decade, the cancer often comes back after the procedure. Now, a team has developed a spray gel embedded with immune-boosting drugs that could help.READ MORE
23rd World Congress on Pediatrics, Neonatology & Primary Care
Nov 22 - Nov 23, 2019